BMC anesthesiology · 2025
Dexmedetomidine versus ketamine as adjuvants in external oblique intercostal plane block for post thoracotomy pain: a randomised trial.
Equivalence TrialСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moharam Saad Ahmed, ElSharkawy Mohammed Said, Abdelhamid Ahmed Shehata, Abdelbadie Asmaa, Kohaf Neveen A, El Rahman Elgaria Mohamed Abd, Attia Amr, Elkashef Ahmed Mohamed
Аннотация
BACKGROUND: The external oblique intercostal plane block (EOIPB) is a novel block that targets explicitly the intercostal nerves to provide pain relief, reduce opioid use, and improve postoperative recovery. This study evaluated the effectiveness of dexmedetomidine (Dex) and Ketamine as adjuvants in EOIPB for post-thoracotomy pain (PTP).
METHODS: This double-blind, randomised trial involved forty adults undergoing open thoracotomy. Cases were distributed equally into two groups. The Ketamine group received bupivacaine 0.25% with Ketamine, while the Dex group received bupivacaine 0.25% with dexmedetomidine.
RESULTS: Patient-required intraoperative fentanyl consumption was not different between groups. Dex provided superior postoperative analgesia to Ketamine, with significantly lower pain scores at 8 h (median 2 vs. 3, p = 0.001) and 12 h (p = 0.035). Time to first rescue analgesia was prolonged (14.65 ± 2.25 vs. 10.26 ± 1.73 h, p < 0.001), and morphine consumption was notably reduced in the Dex group at both 24 h (5.4 ± 1.57 vs. 6.95 ± 1.43 mg, p = 0.003) and 48 h (7.95 ± 1.47 vs. 9.95 ± 1.43 mg, p < 0.001). The two groups did not exhibit any substantial variations in patient satisfaction and the incidences of bradycardia, hypotension, and postoperative nausea and vomiting.
CONCLUSIONS: As an adjuvant in EOIPB, Dex is superior to Ketamine. It provides a longer duration of analgesia, significantly reduces postoperative opioid consumption, and results in lower pain scores at specific time intervals, without a significant difference in adverse effects.
TRIAL REGISTRATION: Registration at clinicaltrials.gov (NCT06331182) Date of registration: 2024-03-17.
METHODS: This double-blind, randomised trial involved forty adults undergoing open thoracotomy. Cases were distributed equally into two groups. The Ketamine group received bupivacaine 0.25% with Ketamine, while the Dex group received bupivacaine 0.25% with dexmedetomidine.
RESULTS: Patient-required intraoperative fentanyl consumption was not different between groups. Dex provided superior postoperative analgesia to Ketamine, with significantly lower pain scores at 8 h (median 2 vs. 3, p = 0.001) and 12 h (p = 0.035). Time to first rescue analgesia was prolonged (14.65 ± 2.25 vs. 10.26 ± 1.73 h, p < 0.001), and morphine consumption was notably reduced in the Dex group at both 24 h (5.4 ± 1.57 vs. 6.95 ± 1.43 mg, p = 0.003) and 48 h (7.95 ± 1.47 vs. 9.95 ± 1.43 mg, p < 0.001). The two groups did not exhibit any substantial variations in patient satisfaction and the incidences of bradycardia, hypotension, and postoperative nausea and vomiting.
CONCLUSIONS: As an adjuvant in EOIPB, Dex is superior to Ketamine. It provides a longer duration of analgesia, significantly reduces postoperative opioid consumption, and results in lower pain scores at specific time intervals, without a significant difference in adverse effects.
TRIAL REGISTRATION: Registration at clinicaltrials.gov (NCT06331182) Date of registration: 2024-03-17.